Cargando…

A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer

In this paper, Au nanocages (AuNCs) loaded with the MRI contrast agent gadolinium (Gd) and capped with the tumor-targeting gene survivin (Sur–AuNC•Gd–Cy7 nanoprobes) were designed and applied as a targeted imaging agent for pancreatic cancer. With its capacity to transport fluorescent dyes and MR im...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Lina, Ren, Shuai, Yue, Yali, Tian, Ying, Wang, Zhongqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221143/
https://www.ncbi.nlm.nih.gov/pubmed/37242788
http://dx.doi.org/10.3390/pharmaceutics15051547
_version_ 1785049386033610752
author Song, Lina
Ren, Shuai
Yue, Yali
Tian, Ying
Wang, Zhongqiu
author_facet Song, Lina
Ren, Shuai
Yue, Yali
Tian, Ying
Wang, Zhongqiu
author_sort Song, Lina
collection PubMed
description In this paper, Au nanocages (AuNCs) loaded with the MRI contrast agent gadolinium (Gd) and capped with the tumor-targeting gene survivin (Sur–AuNC•Gd–Cy7 nanoprobes) were designed and applied as a targeted imaging agent for pancreatic cancer. With its capacity to transport fluorescent dyes and MR imaging agents, the gold cage is an outstanding platform. Furthermore, it has the potential to transport different drugs in the future, making it a unique carrier platform. The utilization of Sur–AuNC•Gd–Cy7 nanoprobes has proven to be an effective means of targeting and localizing survivin-positive BxPC-3 cells within their cytoplasm. By targeting survivin, an antiapoptotic gene, the Sur–AuNC•Gd–Cy7 nanoprobe was able to induce pro-apoptotic effects in BxPC-3 pancreatic cancer cells. The biocompatibility of AuNCs•Gd, AuNCs•Gd–Cy7 nanoparticles, and Sur–AuNC•Gd–Cy7 nanoprobes is evaluated through the hemolysis rate assay. The stability of AuNCs•Gd, AuNCs•Gd–Cy7 nanoparticles, and Sur–AuNC•Gd–Cy7 nanoprobes was evaluated by determining their hydrodynamic dimensions following storage in different pH solutions for a corresponding duration. Excellent biocompatibility and stability of the Sur–AuNC•Gd–Cy7 nanoprobes will facilitate their further utilization in vivo and in vitro. The surface-bound survivin plays a role in facilitating the Sur–AuNC•Gd–Cy7 nanoprobes’ ability to locate the BxPC-3 tumor. The probe was modified to incorporate Gd and Cy7, thereby enabling the simultaneous utilization of magnetic resonance imaging (MRI) and fluorescence imaging (FI) techniques. In vivo, the Sur–AuNC•Gd–Cy7 nanoprobes were found to effectively target and localize survivin-positive BxPC-3 tumors through the use of MRI and FI. After being injected via the caudal vein, the Sur–AuNC•Gd–Cy7 nanoprobes were found to accumulate effectively in an in situ pancreatic cancer model within 24 h. Furthermore, these nanoprobes were observed to be eliminated from the body through the kidneys within 72 h after a single injection. This characteristic is crucial for a diagnostic agent. Based on the aforementioned outcomes, the Sur–AuNC•Gd–Cy7 nanoprobes have significant potential advantages for the theranostic treatment of pancreatic cancer. This nanoprobe possesses distinctive characteristics, such as advanced imaging abilities and specific drug delivery, which offer the possibility of enhancing the precision of diagnosis and efficacy of treatment for this destructive illness.
format Online
Article
Text
id pubmed-10221143
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102211432023-05-28 A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer Song, Lina Ren, Shuai Yue, Yali Tian, Ying Wang, Zhongqiu Pharmaceutics Article In this paper, Au nanocages (AuNCs) loaded with the MRI contrast agent gadolinium (Gd) and capped with the tumor-targeting gene survivin (Sur–AuNC•Gd–Cy7 nanoprobes) were designed and applied as a targeted imaging agent for pancreatic cancer. With its capacity to transport fluorescent dyes and MR imaging agents, the gold cage is an outstanding platform. Furthermore, it has the potential to transport different drugs in the future, making it a unique carrier platform. The utilization of Sur–AuNC•Gd–Cy7 nanoprobes has proven to be an effective means of targeting and localizing survivin-positive BxPC-3 cells within their cytoplasm. By targeting survivin, an antiapoptotic gene, the Sur–AuNC•Gd–Cy7 nanoprobe was able to induce pro-apoptotic effects in BxPC-3 pancreatic cancer cells. The biocompatibility of AuNCs•Gd, AuNCs•Gd–Cy7 nanoparticles, and Sur–AuNC•Gd–Cy7 nanoprobes is evaluated through the hemolysis rate assay. The stability of AuNCs•Gd, AuNCs•Gd–Cy7 nanoparticles, and Sur–AuNC•Gd–Cy7 nanoprobes was evaluated by determining their hydrodynamic dimensions following storage in different pH solutions for a corresponding duration. Excellent biocompatibility and stability of the Sur–AuNC•Gd–Cy7 nanoprobes will facilitate their further utilization in vivo and in vitro. The surface-bound survivin plays a role in facilitating the Sur–AuNC•Gd–Cy7 nanoprobes’ ability to locate the BxPC-3 tumor. The probe was modified to incorporate Gd and Cy7, thereby enabling the simultaneous utilization of magnetic resonance imaging (MRI) and fluorescence imaging (FI) techniques. In vivo, the Sur–AuNC•Gd–Cy7 nanoprobes were found to effectively target and localize survivin-positive BxPC-3 tumors through the use of MRI and FI. After being injected via the caudal vein, the Sur–AuNC•Gd–Cy7 nanoprobes were found to accumulate effectively in an in situ pancreatic cancer model within 24 h. Furthermore, these nanoprobes were observed to be eliminated from the body through the kidneys within 72 h after a single injection. This characteristic is crucial for a diagnostic agent. Based on the aforementioned outcomes, the Sur–AuNC•Gd–Cy7 nanoprobes have significant potential advantages for the theranostic treatment of pancreatic cancer. This nanoprobe possesses distinctive characteristics, such as advanced imaging abilities and specific drug delivery, which offer the possibility of enhancing the precision of diagnosis and efficacy of treatment for this destructive illness. MDPI 2023-05-19 /pmc/articles/PMC10221143/ /pubmed/37242788 http://dx.doi.org/10.3390/pharmaceutics15051547 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Song, Lina
Ren, Shuai
Yue, Yali
Tian, Ying
Wang, Zhongqiu
A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer
title A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer
title_full A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer
title_fullStr A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer
title_full_unstemmed A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer
title_short A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer
title_sort gold nanocage probe targeting survivin for the diagnosis of pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221143/
https://www.ncbi.nlm.nih.gov/pubmed/37242788
http://dx.doi.org/10.3390/pharmaceutics15051547
work_keys_str_mv AT songlina agoldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT renshuai agoldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT yueyali agoldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT tianying agoldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT wangzhongqiu agoldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT songlina goldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT renshuai goldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT yueyali goldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT tianying goldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer
AT wangzhongqiu goldnanocageprobetargetingsurvivinforthediagnosisofpancreaticcancer